Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04841148
Title Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

Her2-receptor negative breast cancer

Therapies

Hydroxychloroquine

Avelumab + Palbociclib

Hydroxychloroquine + Palbociclib

Avelumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.